Sage gets U.S. approval for first postpartum depression therapy
(Corrects paragraphs 1 and 2 to remove reference to "severe")
March 19 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm Sage Therapeutics Inc's drug for postpartum depression, marking the first approval of a treatment specifically developed for the condition that affects a new mother's ability to care for herself or her baby.
The drug, which is administered to new mothers as a single 60-hour intravenous infusion, is chemically identical to the hormone allopregnanolone.
The company said it will price the treatment, to be sold under the brand name Zulresso, at between $20,000 to $35,000, and that it expects broad reimbursement based on feedback from insurers. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Bill Berkrot)
